MaxCyte, Inc. (LON:MXCT – Get Free Report) shares passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 206.79 ($2.75) and traded as low as GBX 160 ($2.13). MaxCyte shares last traded at GBX 165 ($2.19), with a volume of 41,396 shares traded.
MaxCyte Price Performance
The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The company has a market capitalization of £217.81 million, a price-to-earnings ratio of -6.05 and a beta of 1.13. The firm has a 50-day simple moving average of GBX 206.79 and a two-hundred day simple moving average of GBX 279.22.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Further Reading
- Five stocks we like better than MaxCyte
- 3 Small Caps With Big Return Potential
- Meta’s 5 Key Pillars for AI Growth—Zuckerberg’s Bold Vision
- Investing in Travel Stocks Benefits
- Retail Investors Are Betting Big on Rocket Lab—Should You Too?
- Learn Technical Analysis Skills to Master the Stock Market
- GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
